Back to Search
Start Over
Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases.
- Source :
-
Tumori [Tumori] 1998 Jan-Feb; Vol. 84 (1), pp. 39-44. - Publication Year :
- 1998
-
Abstract
- In a prospective trial conducted by the Gruppo Onco Urologico Piemontese, newly diagnosed prostate cancer patients with bone metastases were randomized to receive goserelin (3.6 mg subcutaneously every 4 weeks) or goserelin plus mitomycin at 14 mg/m2 i.v. every 6 weeks. Treatment was planned to be continued until progression. The study was interrupted because of inadequate accrual rate when 63 patients had been recruited. A long-term follow-up (median, 47 months), performed to counterbalance the limited number of patients included, revealed no difference in time to progression and overall survival between the study treatments. However, 56.5% of assessable patients allocated to the chemotherapy arm presented a > or =90% reduction of prostate-specific antigen levels compared with 36.3% in the goserelin group, and previously elevated levels normalized in 73.9% versus 45.4%. Non-progressing patients received 5-7 cycles of mitomycin C with acceptable toxicity, but the cytotoxic treatment was interrupted early in all cases within the first year due to cumulative myelotoxicity. In conclusion, the results, although inconclusive, fail to support a clear advantage in terms of cost/benefit of chemotherapy plus hormone therapy over hormone treatment alone in advanced prostate cancer with bone involvement.
- Subjects :
- Aged
Bone Neoplasms blood
Bone Neoplasms secondary
Disease Progression
Disease-Free Survival
Humans
Male
Middle Aged
Neoplasms, Hormone-Dependent blood
Prospective Studies
Prostate-Specific Antigen blood
Prostatic Neoplasms blood
Prostatic Neoplasms pathology
Survival Analysis
Treatment Outcome
Antibiotics, Antineoplastic therapeutic use
Antineoplastic Agents, Hormonal therapeutic use
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Bone Neoplasms drug therapy
Goserelin therapeutic use
Mitomycin therapeutic use
Neoplasms, Hormone-Dependent drug therapy
Prostatic Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0300-8916
- Volume :
- 84
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Tumori
- Publication Type :
- Academic Journal
- Accession number :
- 9619712
- Full Text :
- https://doi.org/10.1177/030089169808400108